Keros Therapeutics has not yet secured final commercial drug approvals from the United States Food and Drug Administration for any of its proprietary therapeutic candidates, as its entire product pipeline remains in clinical development phases. The company's lead product candidates are currently being evaluated across various early-stage and mid-stage clinical trials targeting rare neuromuscular, pulmonary, and hematologic conditions. While the company has successfully earned valuable regulatory milestones such as Orphan Drug designations from the FDA for specific pipeline candidates like KER-065 to support development, full commercial marketing authorization requires successful completion of late-stage pivotal trials.